At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 440 enrolled
Drug / intervention
Baricitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating Baricitinib and Placebo for Atopic Dermatitis. Completed, enrolled 440 participants across 81 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCanada, Puerto Rico, United States
CollaboratorsIncyte Corporation
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartFeb 2018
Primary CompletionDec 2019
Study CompletionAug 2021
TodayJul 2026
First PostedFeb 15, 2018
Enrollment StartFeb 20, 2018
Primary CompletionDec 9, 2019
Study CompletionAug 16, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.4 years ago
Interventions
Baricitinibdrug
Administered orally
Placebodrug
Administered orally